Merck Ventures: Success in funding early innovation




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Merck Ventures: Success in funding early innovation
Released on: September 26, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Merck Ventures is the strategic, corporate venture capital arm of Merck.
  • Summary
  • Transcript
  • Participants
  • Company
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas.They invest globally in primarily early-stage companies including the creation of spin-offs to leverage Merck‘s science and technology base. Roel Bulthuis, Head of Merck Ventures updates Adrian Dawkes on their latest strategies, exits and successes.
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas.They invest globally in primarily early-stage companies including the creation of spin-offs to leverage Merck‘s science and technology base. Roel Bulthuis, Head of Merck Ventures updates Adrian Dawkes on their latest strategies, exits and successes.
Roel Bulthuis joined the biopharmaceutical division of Merck KGaA, Darmstadt, Germany in 2006 and started MS Ventures in 2009. Previously, Roel was a Director in the Biotech Investment Banking Team at Fortis Bank, where he was responsible for the origination and execution of a wide range of financing and strategic transactions in the biotech sector based out of Amsterdam and New York. Before joining Fortis Bank, Roel worked at Devgen NV in Gent, Belgium, as a business analyst. Roel holds a Msc. in Biopharmaceutical Sciences from Leiden University, the Netherlands, and an MBA in Finance from the Helsinki School of Economics, Finland.
Merck Serono
Merck Serono (EMD Serono in the United States and Canada) is a pharmaceutical company headquartered in Geneva, Switzerland.[1] In September 2006, Merck KGaA announced its intent to purchase the majority of Serono shares from Ernesto Bertarelli and the Bertarelli family. The Merck-Serono merger was announced on September 21, 2006. Merck KGaA and Serono operated as distinct entities until at least January 2007. As of January 5, 2007, Merck held the majority shares of Serono. The new company is called Merck Serono International S.A.